Cover Image

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Jie Meng,1 Johanna Lister,1 Anne-Lise Vataire,2 Roman Casciano,1 Jerome Dinet2 1Analytica Laser, London, UK; 2Ipsen Pharma, Boulogne-Billancourt, France Purpose: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with ad...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meng J (Author), Lister J (Author), Vataire AL (Author), Casciano R (Author), Dinet J (Author)
Format:	Book
Published:	Dove Medical Press, 2018-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
by: Janet Brown, et al.
Published: (2024)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
by: SiNi Li, et al.
Published: (2021)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni E, et al.
Published: (2014)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab
by: Maciej Niewada, et al.
Published: (2023)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
by: Emeline Colomba, et al.
Published: (2022)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022)

Role of everolimus in the treatment of renal cell carcinoma
by: Saby George, et al.
Published: (2009)

Cabozantinib-associated acquired perforating dermatosis
by: Denis Smirnov, MD, PhD, et al.
Published: (2024)

Variables Affecting the Preparation and Characterization of Axitinib as Oral Niosmoes
by: Ibtihal Abdulkadhim Dakhil, et al.
Published: (2024)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
by: Leonetti A, et al.
Published: (2017)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian "Real-Word" SAX study
by: Carmine D'Aniello, et al.
Published: (2016)

Clinical utility of nivolumab in the treatment of advanced melanoma
by: Asmar R, et al.
Published: (2016)

HPLC method development and validation for the estimation of axitinibe in rabbit plasma
by: Achanta Suneetha, et al.
Published: (2017)

PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
by: M. V. Avxentyeva, et al.
Published: (2015)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
by: Sabrina Rossetti, et al.
Published: (2017)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
by: Jingyang Su, et al.
Published: (2024)

Method development and validation of cabozantinib by LC-MS/MS
by: Punna Venkateshwarlu, et al.
Published: (2022)

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China
by: Kehui Meng, et al.
Published: (2024)

Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
by: Bruno Bregman, et al.
Published: (2020)

Photosensitive rash induced by nivolumab
by: Francisco J. Navarro-Triviño, et al.
Published: (2022)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
by: Colombo JR, et al.
Published: (2014)

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report
by: T. Simundic, et al.
Published: (2018)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors
by: Darren MC Poon, et al.
Published: (2023)

Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
by: Hiroaki Kanzaki, et al.
Published: (2023)

Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model
by: Liu C, et al.
Published: (2023)

Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines
by: Nai-Xiong Peng, et al.
Published: (2015)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Yan Li, et al.
Published: (2022)

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
by: Edouard Chasseuil, et al.
Published: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Everolimus in Erdheim-Chester disease
by: Mohamed A. Hussein, et al.
Published: (2013)

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Venur VA, et al.
Published: (2017)

Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells
by: Zeng YZ, et al.
Published: (2018)